| ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff Nature reviews Clinical oncology 12 (10), 573-583, 2015 | 615 | 2015 |
| Treatment landscape of triple-negative breast cancer—expanded options, evolving needs G Bianchini, C De Angelis, L Licata, L Gianni Nature reviews Clinical oncology 19 (2), 91-113, 2022 | 610 | 2022 |
| Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ... Breast cancer research and treatment 136, 795-804, 2012 | 245 | 2012 |
| Towards personalized treatment for early stage HER2-positive breast cancer K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ... Nature Reviews Clinical Oncology 17 (4), 233-250, 2020 | 241 | 2020 |
| FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ... Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016 | 156 | 2016 |
| The changing role of ER in endocrine resistance A Nardone, C De Angelis, MV Trivedi, CK Osborne, R Schiff The Breast 24, S60-S66, 2015 | 141 | 2015 |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ... JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020 | 125 | 2020 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 125 | 2019 |
| Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy M Giuliano, H Hu, YC Wang, X Fu, A Nardone, S Herrera, S Mao, ... Clinical Cancer Research 21 (17), 3995-4003, 2015 | 122 | 2015 |
| The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer R Jeselsohn, C De Angelis, M Brown, R Schiff Current oncology reports 19, 1-8, 2017 | 113 | 2017 |
| Embryonic transcription factor SOX9 drives breast cancer endocrine resistance R Jeselsohn, MI Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, ... Proceedings of the National Academy of Sciences 114 (22), E4482-E4491, 2017 | 112 | 2017 |
| HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ... Clinical Cancer Research 23 (17), 5123-5134, 2017 | 111 | 2017 |
| Tamoxifen resistance in breast cancer is regulated by the EZH2–ERα–GREB1 transcriptional axis Y Wu, Z Zhang, ME Cenciarini, CJ Proietti, M Amasino, T Hong, M Yang, ... Cancer research 78 (3), 671-684, 2018 | 95 | 2018 |
| Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance M Bi, Z Zhang, YZ Jiang, P Xue, H Wang, Z Lai, X Fu, C De Angelis, ... Nature cell biology 22 (6), 701-715, 2020 | 91 | 2020 |
| Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer C Guarducci, M Bonechi, M Benelli, C Biagioni, G Boccalini, D Romagnoli, ... NPJ breast cancer 4 (1), 38, 2018 | 91 | 2018 |
| Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing … MF Rimawi, C De Angelis, A Contreras, F Pareja, FC Geyer, KA Burke, ... Breast cancer research and treatment 167, 731-740, 2018 | 89 | 2018 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 88 | 2018 |
| Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer G Arpino, C De Angelis, M Giuliano, A Giordano, C Falato, ... Oncology 77 (Suppl. 1), 23-37, 2010 | 84 | 2010 |
| Immune response against head and neck cancer: biological mechanisms and implication on therapy F Perri, F Ionna, F Longo, GDV Scarpati, C De Angelis, A Ottaiano, G Botti, ... Translational oncology 13 (2), 262-274, 2020 | 69 | 2020 |
| De-escalation of treatment in HER2-positive breast cancer: determinants of response and mechanisms of resistance J Veeraraghavan, C De Angelis, JS Reis-Filho, T Pascual, A Prat, ... The Breast 34, S19-S26, 2017 | 66 | 2017 |
Rachel SchiffBaylor College of Medicine在 bcm.edu 的电子邮件经过验证
